BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 27059853)

  • 21. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
    Triviño Ibáñez EM; Muros MA; Torres Vela E; Llamas Elvira JM
    Endocrine; 2016 Mar; 51(3):490-8. PubMed ID: 26224589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET/MRI in the Diagnosis of Hormone-Producing Pituitary Microadenoma: A Prospective Pilot Study.
    Wang H; Hou B; Lu L; Feng M; Zang J; Yao S; Feng F; Wang R; Li F; Zhu Z
    J Nucl Med; 2018 Mar; 59(3):523-528. PubMed ID: 28775202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iodine-131 SPET/CT and 18F-FDG PET/CT for the identification and localization of mediastinal lymph node metastases from differentiated thyroid carcinoma.
    Xu YH; Shen CT; Xue YL; Qiu ZL; Luo QY
    Hell J Nucl Med; 2013; 16(3):199-203. PubMed ID: 24251307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
    Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
    Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
    Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and Prognostic Value of PET/CT Imaging with Combination of
    Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
    Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.
    Manohar PM; Beesley LJ; Bellile EL; Worden FP; Avram AM
    Clin Nucl Med; 2018 Sep; 43(9):641-647. PubMed ID: 30015659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer.
    Wang C; Zhang X; Yang X; Li H; Cui R; Guan W; Li X; Zhu Z; Lin Y
    Endocr Relat Cancer; 2018 Jun; 25(6):653-663. PubMed ID: 29618578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic performance of [
    Jha A; Patel M; Ling A; Shah R; Chen CC; Millo C; Nazari MA; Sinaii N; Charles K; Kuo MJM; Prodanov T; Saboury B; Talvacchio S; Derkyi A; Del Rivero J; O'Sullivan Coyne G; Chen AP; Nilubol N; Herscovitch P; Lin FI; Taieb D; Civelek AC; Carrasquillo JA; Pacak K
    Eur Radiol; 2024 Apr; ():. PubMed ID: 38625612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffusion-weighted MRI is not superior to FDG-PET/CT for the detection of neck recurrence in well-differentiated thyroid carcinoma.
    Vera P; Edet-Sanson A; Quieffin F; Le Cloirec J; Bertrand AS; Cailleaux M; Menard JF; Lussey-Lepoutre C; Callonnec F
    Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):311-320. PubMed ID: 28478664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.
    Freudenberg LS; Antoch G; Frilling A; Jentzen W; Rosenbaum SJ; Kühl H; Bockisch A; Görges R
    Eur J Nucl Med Mol Imaging; 2008 May; 35(5):950-7. PubMed ID: 18193222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.